Other grades of this product :
| Product Name: | ESI 09 | | Synonyms: | α-[(2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-3-isoxazolepropanenitrile;ESI 09;ESI09;ESI-09;(E)-3-(5-tert-butylisoxazol-3-yl)-2-(2-(3-chlorophenyl)hydrazono)-3-oxopropanenitrile;α-[2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-b-oxo-3-isoxazolepropanenitrile;alpha-[(3-Chlorophenyl)hydrazono]-5-(1,1-dimethylethyl)-beta-oxo-3-isoxazolepropanenitrile;3-Isoxazolepropanenitrile, α-[2-(3-chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo- | | CAS: | 263707-16-0 | | MF: | C16H15ClN4O2 | | MW: | 330.77 | | EINECS: | | Product Categories: | Inhibitors | | Mol File: | 263707-16-0.mol |
| ESI 09 Chemical Properties |
| Melting point | >175°C (dec.) | | storage temp. | 2-8°C | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | color | , faint yellow to dark orange |
| ESI 09 Usage And Synthesis |
| Uses | ESI 09 acts as an EPAC inhibitor, preventing EPAC-mediated insulin release form β-pancreatic cells. Selective control for EPAC over PKA and decreases migration and invasion of AsPc-1 and PANC-1 pancreatic cancer cells. | | Biochem/physiol Actions | ESI-09 is a potent, specific inhibitor of EPAC (exchange protein directly activated by cAMP). ESI-09 inhibits EPAC1 and EPAC2 with IC50 values of 3.2 and 1.4 μM, respectively, with no activity against PKA at 25 μM. In pancreatic cell lines, the compound blocks phosphorylation of Akt and insulin secretion. ESI-09 inhibits migration of pancreatic cancer cell lines. |
| ESI 09 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye